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CASE PRESENTATION
A 48-year-old woman was referred for a second opinion
regarding paroxysmal hypertension. At the time of
referral, she had an 18-month history of acute
hypertensive crisis necessitating hospitalization. She had
already undergone evaluation by primary care and
endocrinology prior to this presentation.
Prior to 18 months ago, she had no history of
hypertension and her past medical history was only
significant for two previous pregnancies, neither of which
was accompanied by hypertension. She described herself
as healthy and exercised daily prior to onset of these
hypertensive attacks. She generally felt well rested.
She saw her primary care physician regularly for health
care maintenance and reported that her blood pressure
prior to 18 months ago usually ranged from 110 to
120 mm Hg systolic, with a heart rate of 60–70 beats
per minute. She had no family history of hypertension.
She was divorced and had two children. She did
not smoke, drank one to two cups of coffee per day,
drank three to four glasses of wine in the evenings,
denied illicit drug use, and had no known drug allergies.
At the time of our initial evaluation, she was taking
atenolol 25 mg daily as prescribed by her primary
care physician. She denied use of non-steroidal
anti-inflammatory drugs, vitamins, herbals, or other
over the counter medications.
Beginning 18 months ago, she described her hypertensive
episodes as sudden, unprovoked, unrelated to stress or panic,
and accompanied by various symptoms including headache,
nausea, tremors, and diarrhea. She described an accompany-
ing sense of dread or panic though only after the other
symptoms manifested. She was not aware that these episodes
included hypertension until she sought care in a local
emergency department and found her blood pressure to be
260/140 mm Hg. She had seen a medical professional at least
a dozen times during those 18 months and was hospitalized
at least three times for a period of 3 to 4 days while
undergoing examination for secondary causes of hyperten-
sion. In recent months, she had noted an acceleration in the
frequency of the episodes from once or twice per month to
three to four times per week. The patient reported that she
often left the emergency room with improved but still
elevated blood pressure in the 160/90 range. Her physicians
tried multiple single-agent medications, including amlodi-
pine 5 mg daily, HCTZ 25 mg daily, metoprolol 100 mg daily,
and labetolol 200 mg twice daily, which were variably titrated
upwards during hypertensive episodes. Between attacks, her
blood pressure was 100–120 mm Hg systolic or lower;
however, she experienced symptomatic hypotension between
the episodes necessitating that the medications be reduced or
stopped entirely.
The results of multiple plasma and 24-h urine tests,
including plasma renin and aldosterone, urine catechola-
mines, and 5-hydroxyindoleacetic acid (5-HIAA) (at least
one of which was collected during a hypertensive episode)
were reviewed by us and were normal and not suggestive of
pheochromocytoma, primary aldosteronism, or carcinoid
syndrome (Table 1). A fundoscopic examination documented
from at least one of her emergency room visits was stated as
normal. She had also undergone an abdominal computed
tomographic scan that demonstrated no adrenal masses and
normal appearing kidneys. An echocardiogram performed a
few months prior to our evaluation, however, did have
evidence of concentric left ventricular hypertrophy.
On examination, she was a healthy-appearing woman in
no distress. Her blood pressure was 153/99 mm Hg with a
pulse of 63, she weighed 138 pounds (62.6 kg) with a height
of 65.5 inches (166 cm), and her body mass index was
22.5 kg m2. Her physical examination was unremarkable.
She did not have enlarged tonsils or any craniofacial or soft
tissue abnormalities. No thyroid abnormalities, skin changes,
or abdominal bruits were detected. Fundoscopic examination
was unremarkable. A urinalysis was normal and urine
microscopy was negative. Electrolytes were unremarkable
showing creatinine at 0.7 mg per 100 ml and serum
potassium at 3.9 mg per 100 ml.
On further questioning with regard to psychological
stressors, she said that has been divorced for 5 years and
had a history of physical and emotional abuse by her
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ex-husband. She reported that she had been in psychotherapy
for several years with a non-physician psychotherapist and
was not on any psychiatric medications. She is a single
mother of two school-aged children and currently attempting
to start a new business. She felt stress with regard to her
business, as it would be her primary means of income.
She was open about her alcohol intake, but denied signs
or symptoms consistent with dependence. Her alcohol intake
of 3–4 glasses of wine per day has been unchanged for 10
years and was confirmed by previous primary care notes in
the medical record. When questioned about her specific
activities and frame of mind on the day or two preceding
a number of her recent attacks, she adamantly denied overt
anxiety, fear, or emotional distress. In fact, one of the most
recent attacks occurred on a weekend while she was at
the beach relaxing with her oldest daughter and enjoying
a pleasant afternoon.
CLINICAL DIAGNOSIS
She was clinically diagnosed with pseudopheochromocytoma.
CLINICAL FOLLOW-UP
We continued atenolol, added doxazosin 1 mg twice per day,
and added paroxetine 10 mg per day to her medical regimen.
She came for follow-up 3 weeks later and reported no new
hypertensive crisis since starting the new regimen. Her usual
systolic blood pressure was around 110 mm Hg. She still
experienced systolic blood pressures in the range of 150 to
160 mm Hg, but only when exercising, an activity that she
recently resumed. A telephonic interview 4 months later
revealed no further hypertensive episodes and a maximum
systolic blood pressure of 130 mm Hg, even while exercising.
She continued to drink 3–4 glasses of wine per day, and
the psychosocial stressors of starting a business and
difficult interactions with her ex-husband were unchanged
at follow-up.
DISCUSSION
In the clinical evaluation of the patient with a recent onset of
paroxysmal hypertension, secondary causes of hypertension
must be investigated. The most common causes of secondary
hypertension, whether sustained or episodic, include reno-
vascular disease, primary aldosteronism, renal parenchymal
disease, obstructive sleep apnea, hyperthyroidism, Cushing’s
syndrome, and pheochromocytoma.1 The syndrome of a
catecholamine-secreting pheochromocytoma (Table 2) is one
of the most recognized form of secondary hypertension,
although among the rarest form ultimately diagnosed with
only 0.1–0.6% of hypertension cases attributed to this
etiology.2 Pheochromocytoma must be considered, however,
as it is potentially lethal when unrecognized as it can lead to
cerebral vascular accidents or myocardial infarctions as a
consequences of the effects of secreted catecholamines.3
The term pseudopheochromocytoma has been used to
describe paroxysmal hypertension with a spectrum of signs
and symptoms consistent with catecholamine excess, but in
the absence of a clinical diagnosis of pheochromocytoma. It
was used by Kuchel4 in 1981 to describe a hyperadrenergic
form of essential hypertension with labile blood pressure, low
conjugated catecholamines, and commonly associated with
emotional triggers. He reinforced the predominance of overt
emotionally provoked bouts of hypertension in this popula-
tion in a 10-year retrospective analysis from 1998.5 Similarly
in 1985, Takabatake et al.6 described a series of patients
meeting these criteria.
The term pseudopheochromocytoma has since been
variably used in the literature to describe syndromes of
Table 2 | Common symptoms associated with
pheochromocytoma
Sustained or episodic hypertension
Headache
Diaphoresis
Palpitations
Pallor
Nausea
Flushing
Psychological symptoms
Table 1 | Laboratory results
Electrolytes Urinalysis and urine microscopy
Na: 134 mmol l1
(ref. 136–142 mmol l1)
Specific gravity, 1.004
K: 3.9 mmol l1 (ref. 3.5–5.0 mmol l1) pH 6.5
Cl: 98 mmol l1 (ref. 98–108 mmol l1) No albumin, ketones, or nitrites
CO2: 27 mmol l
1
(ref. 23–32 mmol l1)
RBC/hpf: 3–5
BUN: 8 mg per 100 ml (ref. 9–25 mg
per 100 ml)
WBC/hpf: none
Creatinine: 0.7 mg per 100 ml
(ref. 0.7–1.3 mg per 100 ml)
Casts: none
Other plasma tests 24-h urine collection
Plasma renin: 1.5 ng ml1
(ref. 0.2–1.6 ng ml1)
Total volume, 2650 ml
Plasma aldosterone: 27.9 ng per
100 ml (ref. 4–31 ng per 100 ml)
Na: 130 mmol
(ref. 75–200 mmol)
TSH 1.6 mIU l1 (normal 0.5–5.0) K: 53 mmol (ref. 40–80 mmol)
Creatinine: 1193 mg
(ref. 800–1800 mg)
Other urine tests
Urine toxicology screen: negative
Aldosterone: 13.8 mcg
(ref. 6–25 mcg)
Epinephrine: 8 mcg
(ref. 0–25 mcg)
Norepinephrine: 61 mcg
(ref. 0–100 mcg)
Dopamine: 231 mcg
(ref. 60–440 mcg)
Free cortisol: 2.7 mcg
(ref. 0–45 mcg)
Normetanephrines: 419 mcg
(ref. 50–650 mcg)
Metanephrines: 117 mcg
(ref. 30–350 mcg)
Vanillyl mandelic acid (VMA):
2.1 mg (0–7 mg)
5-HIAA: 4 mg (ref. 0–8 mg)
BUN, blood urea nitrogen; 5-HIAA, 5-hydroxyindoleacetic acid; hpf, high-power field;
TSH, thyroid-stimulating hormone.
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paroxysmal hypertension that may include biochemical
evidence of catecholamine excess in the absence of an
identifiable tumor. Anti-Parkinsonian drugs and obstructive
sleep apnea have been described to cause elevations in plasma
catecholamines resulting in labile hypertension.7,8 Pre-
eclampsia resulting in an elevation of urinary catecholamine
can also mimic pheochromocytoma.9 There is also a
description of a state of catecholamine excess indirectly
resulting from a non-catecholamine-secreting tumor as
pseudopheochromocytoma.10 More consistent with Kuchel’s
original description of pseudopheochromocytoma, however,
Mann and co-workers used the term to describe paroxysmal
hypertension in the absence of biochemical catecholamine
excess, but Mann11 also limited the description to the absence
of immediately identifiable panic or emotional distress.
Consistent with the description by Mann, we will limit the
use of the term pseudopheochromocytoma in the context of
this discussion to describe a syndrome of unexplained
paroxysmal hypertension without biochemical evidence of
catecholamine excess. Borrowing from that description,
paroxysmal hypertension differs from panic attack in that
there is a ‘clear relationship between blood pressure elevation
and stress or emotional distress’ with panic attacks.11
Therefore, in addition to the otherwise unexplained paroxy-
sms of hypertension, we will specify that pseudopheo-
chromocytoma should exclude provocation from emotional
distress as an underlying etiology.
In the case described here, paroxysmal hypertension was
the predominant feature, and causes of paroxysmal hyperten-
sion with respect to catecholamine excess are presented in
Table 3. Several of these etiologies were ruled out in our
patient by the medical history, laboratory, and imaging
studies. Although she did not have a formal sleep study, she
did not have a history or physical exam suggestive of sleep
apnea. As she was evaluated for catecholamine excess both
during and between hypertensive crisis, paroxysmal hyper-
tension from catecholamine excess states as listed in Table 3A
was ruled out. A differential diagnosis for paroxysmal
hypertension without catecholamine excess could be sum-
marized in Table 3B. She adamantly denied preceding anxiety
states or panic attacks, although she did become emotionally
distressed when a hypertensive crisis was underway. Thyro-
toxicosis and carcinoid were ruled out by laboratory analysis,
and there was no history or evidence of alcohol withdrawal.
Pseudopheochromocytoma (as defined above) was therefore
diagnosed and treatment started.
Literature suggests the treatment of pseudopheochromo-
cytoma consists of a combination of b- and a1-adrenergic
blockade along with psychopharmacologic therapy.11 This
strategy of dual adrenergic blockage in pseudopheochromo-
cytoma is supported by a study by Hamada et al., which
demonstrated that the hemodynamic response to a valsalva in
a population with pseudopheochromocytoma was much
greater than that of the population with pheochromocytoma.
Hemodynamic monitoring implied a hyperactivity of both
the b- and a1-adrenergic receptor functions in pseudopheo-
chromocytoma. This is in contrast to the population with
true pheochromocytoma, which showed a blunted response
of both adrenergic systems due to desensitization associated
with chronic catecholamine excess. Administration of a
b- and a1-blocker to the population with pseudopheochro-
mocytoma resulted in the normalization of hemodynamics
and is thought to be the mechanism of symptom relief.12
A less well-described and certainly perplexing aspect of
pseudopheochromocytoma is the absence of overt emotional
distress yet reliance on psychopharmacologic therapy in
addition to adrenergic blockade. Our patient was seeing a
non-physician psychotherapist; however, she was not receiv-
ing psychopharmacologic therapy. She did admit to psycho-
logical stressors such as a history of abuse, starting a new
business, and fear of failure on behalf of her children,
however, she adamantly denied overt panic attacks or
emotional distress preceding her attacks. Mann11 did identify
repression of emotions, however, as a common feature of
patients included in his case series. In this context,
antidepressants and anxiolytics are aimed at treating a
possible subclinical psychological disorder that predisposes
a certain population to these paroxysms of hypertension.
There is only anecdotal evidence regarding the type or
duration of this aspect of therapy, but resolution of
symptoms with treatment often occurs in a short period of
time in this selected population, as in our patient. After an
18-month history of new onset, unprovoked paroxysmal
hypertension treated with several other agents to the point of
hypotension between attacks, ultimately only the combina-
tion of relatively low-dose b-blockade, a1-blockade, and an
antidepressant produced a rapid and complete resolution of
her symptoms in the absence of any change in other
parameters such as her alcohol intake or psychosocial
stressors.
SUMMARY
In conclusion, clinicians should recognize secondary causes
of paroxysmal hypertension specifically with regard to the
patient suspected of having pheochromocytoma. The absence
of a detectable catecholamine excess state in cases of
Table 3 | Paroxysmal hypertension and catecholamine excess
states
A. Paroxysmal hypertension associated with plasma or urinary
catecholamine excess
Pheochromocytoma
Obstructive sleep apnea
Anti-Parkinsonian drugs
Cocaine use
Baroreflex failure
B. Paroxysmal hypertension in the absence of biochemical catecholamine
excess
Anxiety state (panic attack)
Thyrotoxicosis
Pseudopheochromocytoma
Alcohol withdrawal
Carcinoid syndrome
534 Kidney International (2008) 74, 532–535
t h e r e n a l c o n s u l t J Hunt and J Lin: Paroxysmal hypertension in a 48-year-old woman
paroxysmal hypertension has a narrow differential, and one
should not overlook the diagnosis of pseudopheochromo-
cytoma especially in the absence of overt anxiety states. The
syndrome of pseudopheochromocytoma as described here
can be effectively treated and long-term management
achieved with the combined regimen of b- and a1-adrenergic
blockade along with psychopharmacologic therapy.
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